Rick L. Tarleton

Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection.

Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR.

Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.

Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi.

Chagas disease: a role for autoimmunity?

TcruziDB: an integrated Trypanosoma cruzi genome resource.

Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice.

Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection.

A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results.

New approaches in vaccine development for parasitic infections.

CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes.

A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi.

Immune system recognition of Trypanosoma cruzi.

TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection.

The challenges of Chagas Disease-- grim outlook or glimmer of hope.

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection.

High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection.

HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease.

Eliminating Chagas disease: challenges and a roadmap.

Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi.

Chromosome level assembly of the hybrid Trypanosoma cruzi genome.

Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection.

CD8+ T cells in Trypanosoma cruzi infection.

The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi.

Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence.

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina.

Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.

CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization.

Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Methodological advances in drug discovery for Chagas disease.

Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.

Transgenic parasites accelerate drug discovery.

Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.

Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.

Is Chagas disease really the "new HIV/AIDS of the Americas"?

A systematic review of high quality diagnostic tests for Chagas disease.

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence.

Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen.

Frequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection.

The Trypanosoma cruzi flagellum is discarded via asymmetric cell division following invasion and provides early targets for protective CD8⁺ T cells.

Chagas disease and the london declaration on neglected tropical diseases.

CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi.

Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets.

CD8+ T cells in Trypanosoma cruzi infection.

A framework for ontology-based question answering with application to parasite immunology.

Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Chagas Disease: A Solvable Problem, Ignored.

Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi.

The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to in Serodiscordant Subjects.

Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.

Spontaneous dormancy protects during extended drug exposure.

Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Protozoan persister-like cells and drug treatment failure.

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against in Acylaminobenzothiazole Series.

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.

Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion.

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease.

Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease.

A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses.

Reduced Trypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease.

High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA.